Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
2025 Environmental, Social and Governance Report
Regulatory Filings
2026-04-29 English
2025 ANNUAL REPORT
Regulatory Filings
2026-04-29 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 1% confidence The document is a corporate stock exchange announcement detailing the grant of share options and restricted share units under the company’s Post-IPO equity incentive schemes. It is not an earnings release, management report, AGM presentation, or legal update. It does not announce actual share repurchases nor insider trades, but rather a planned issuance of equity-linked instruments requiring shareholder approval. This falls squarely under “Share Issue/Capital Change” (SHA).
2026-04-13 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026
Regulatory Filings Classification · 1% confidence The document is the HKEX FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules, detailing movements in authorised and issued share capital, share options, capital changes, and public float confirmation. It is a recurring regulatory submission to the stock exchange and does not fit specialized categories like an earnings release, AGM materials, or a proxy statement. Therefore, it is classified as a general regulatory filing.
2026-04-09 English
(Revised) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026
Share Issue/Capital Change Classification · 1% confidence The document is an HKEX Form FF301 monthly return detailing movements in authorised share capital, issued shares (including share option exercises), and other capital changes of the issuer. It is not an earnings release, management change, or AGM material, but a regulatory submission focused on share issuance and capital structure movements. Therefore it best fits the “Share Issue/Capital Change” category (Code: SHA).
2026-04-09 English
(Revised) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) filed with the Hong Kong Exchange under Listing Chapter 19B, detailing movements in authorised share capital, issued shares, share options, public float sufficiency, etc. It is a compliance/regulatory filing rather than a standalone report (like an annual or interim report), a management/call transcript, a major transaction, or a dividend/issuance announcement. It does not announce a one-off share issue event but provides periodic reporting of share movements. Therefore it falls under the fallback category "Regulatory Filings (RNS)."
2026-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.